| Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. | |
MedLine Citation:
|
PMID: 23299930 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONCLUSION: Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation. EF24 overcomes sorafenib resistance through VHL-dependent HIF-1α degradation and NF-κB inactivation. EF24 in combination with sorafenib represents a promising strategy for HCC. |
Authors:
|
Yingjian Liang; Tongsen Zheng; Ruipeng Song; Jiabei Wang; Dalong Yin; Luoluo Wang; Haitao Liu; Lantian Tian; Xiang Fang; Xianzhi Meng; Hongchi Jiang; Jiaren Liu; Lianxin Liu |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2013-03-14 |
Journal Detail:
|
Title: Hepatology (Baltimore, Md.) Volume: 57 ISSN: 1527-3350 ISO Abbreviation: Hepatology Publication Date: 2013 May |
Date Detail:
|
Created Date: 2013-04-23 Completed Date: 2013-07-05 Revised Date: 2014-07-31 |
Medline Journal Info:
|
Nlm Unique ID: 8302946 Medline TA: Hepatology Country: United States |
Other Details:
|
Languages: eng Pagination: 1847-57 Citation Subset: IM |
Copyright Information:
|
Copyright © 2013 American Association for the Study of Liver Diseases. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anoxia / physiopathology* Antineoplastic Agents / pharmacology, therapeutic use Apoptosis / drug effects Benzylidene Compounds / pharmacology* Carcinoma, Hepatocellular / drug therapy*, metabolism, pathology Cell Line, Tumor Cell Movement / drug effects Cell Survival / drug effects Drug Resistance, Neoplasm / drug effects* Drug Therapy, Combination Humans Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors*, metabolism Liver Neoplasms / drug therapy*, metabolism, pathology Male Mice Mice, Inbred BALB C Mice, Nude NF-kappa B / metabolism Niacinamide / analogs & derivatives*, pharmacology, therapeutic use Phenylurea Compounds / pharmacology, therapeutic use* Piperidones / pharmacology* Treatment Outcome Von Hippel-Lindau Tumor Suppressor Protein / metabolism* Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/3,5-bis(2-fluorobenzylidene)piperidin-4-one; 0/Antineoplastic Agents; 0/Benzylidene Compounds; 0/HIF1A protein, human; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/NF-kappa B; 0/Phenylurea Compounds; 0/Piperidones; 0/sorafenib; 25X51I8RD4/Niacinamide; EC 6.3.2.19/Von Hippel-Lindau Tumor Suppressor Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outco...
Next Document: Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to ?-tocopheryl succi...